EARNING RECAP

Amgen Inc

#AMGN 2019 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q1 $3.56 est. $3.48 $5.56B est. $5.52B -1.77% ($176.14 closing price) $178.50 $171.25 raises FY19 adjusted EPS view to $13.25-$14.30 from $13.10- $14.30; FY19 revenue view to $22B- $22.9B from $21.8B- $22.9B
#AMGN 2018 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 adjusted $3.42 est. $3.28 $6.23B est. $5.87B -3.77% ($184.86 closing price) $189.76 $179.65 Q4 Repatha sales up 62%; Neulast up 5%; Enbrel sales down 8%; sees Fy19 adjusted EPS $13.10-$14.30 est. $14.62
Q3 adjusted $3.69 est. $3.45 $5.9B est. $5.77B +1.96% ($192.79 closing price) $195.33 $189.04 raises FY18 adjusted EPS & Revenuew view -$14-$14.25 from $13.4- $14 consensus $14.02; $23.2B-$23.5B from $22.5B-$23.2B est. $23.17B; Fy18 CapEx $700M; Q3 product sales up 1% globally
Q2 adjusted $3.83 est. $3.54 $6.1B est. $5.73B -.82% ($192.44 closing) $196.22 $189.57 raises FY18 adj. EPS & Revenues; $13.30-$14 from $12.8-$13.70, est. $13.75; $22.5B-$23.2B from $21.9B-$22.8B consensus $22.59B; FY18 CAPEX $750M
Q1 adjusted $3.47 est. $3.24 $5.6B est. $5.43B +1.68% ($174.83 closing) $175.44 $170.34 Q1 Repatha sales up 151%; Ups total revenue guidance to $21.9B -$22.8Bfrom $21.88B -$22.61B
#AMGN 2017 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 adjusted EPS $2.89 est. $3.03 $5.8B est. $5.83B. +0.78% $192.60 $183.01 announces additional $10B share repurchase program
Q3 $3.27 vs. $3.11 $5.8B vs. $5.76B -.55% ($176.52 closing) $177.44 $169.68 *BTD reaction off lows*raises FY '17 eps view $12.50 to $12.70 from $12.15-$12.65
Q2 Adjusted EPS $3.27 vs $3.11 $5.8b vs $5.67b -2.76% or -5.00 points, closed at 175.89 $178.85 $175.20 Raises guidance. FY17 $12.15-12.60
Q1 Adjust $3.15 Vs $3.0 $5.5B vs $5.61B -1.15% @ $162.72 closed $163.43 $160.00 -3.10% @ 159.50 after hours. Embel sale down 15%. Stock slide, but dips action throughout the day.

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.